Recombinant Human Glycophorin-A/GYPA/CD235a protein (RP02835)

Anti-GPA Antibody immobilized on CM5 Chip can bind Human GPA, hFc Tag with an affinity constant of 0.72 μM as determined in SPR assay (Biacore T200).

Recombinant Human Glycophorin-A/GYPA/CD235a protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 45-65kDa.

The purity of Human Glycophorin-A is greater than 95% as determined by SEC-HPLC.

All(3)|

货号: RP02835

详细信息

种属

Human

表达宿主

HEK293 cells

Calculated MW

33.90 kDa

Observed MW

45-65 kDa

标签

C-hFC

纯度

> 95% as determined by HPLC

内毒素

<0.01EU/μg

制剂

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

描述

Recombinant Human Glycophorin-A Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ser20-Glu91) of human Glycophorin-A (Accession #NP_002090.4) fused with a hFc tag at the C-terminus.

储存

Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

生物活性

Anti-GPA Antibody immobilized on CM5 Chip can bind Human GPA, hFc Tag with an affinity constant of 0.72 μM as determined in SPR assay (Biacore T200).

复溶

Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！

客户数据及评论 (0)

折叠内容

背景信息

Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.

基因ID

2993

Swiss Prot

P02724-1

别名

PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN

研究领域